Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.

April 22, 2019

Cellectis Plans Clinical Trial to Test Donor-derived CAR T-cell Therapy, Possible Multiple Myeloma Treatment

News

Cellectis announced plans to open a Phase 1 clinical trial to evaluate UCARTCS1 — its first allogeneic (donor-derived) CAR T-cell therapy for multiple myeloma patients — at several sites in the U.S. The ... Read more

April 17, 2019

Trial to Evaluate Daratumumab/Revlimid as Maintenance for Some Multiple Myeloma Patients

News

Janssen Biotech is planning a new Phase 3 clinical trial to explore a combination of under-the-skin daratumumab plus Revlimid (lenalidomide) as a maintenance treatment for multiple myeloma patients who received an ... Read more

April 12, 2019

Janssen Seeks Approval of Darzalex Add-on for Newly Diagnosed Multiple Myeloma Patients in Japan

News

Janssen has submitted an application to Japanese authorities seeking the approval of Darzalex (daratumumab) — in combination with standard Revlimid (lenalidomide) and dexamethasone — for the treatment of newly diagnosed multiple myeloma patients ineligible for high-dose chemotherapy and stem cell ... Read more

March 18, 2019

NantKwest, ProMab Partner to Develop Natural Killer Cell Therapy for Multiple Myeloma, Other Blood Cancers

News

NantKwest and ProMab Biotechnologies are collaborating to develop a novel immunotherapy for multiple myeloma using natural killer (NK) cells that target the B-cell maturation antigen, or BCMA. The therapy, called ... Read more

January 11, 2019

Study Tracing Myeloma Progression from Precursor Conditions Seeks Participants

News

A study is recruiting participants to examine the molecular changes that occur when precursor conditions develop into full-blown multiple myeloma, information that can then be used to design therapies ... Read more

January 9, 2019

Janssen Seeks Darzalex Approval for Certain Newly Diagnosed Multiple Myeloma Patients in Japan

News

Janssen Pharmaceutical has submitted an application to Japanese authorities requesting that Darzalex (daratumumab) be approved, in combination with standard therapy, to treat newly diagnosed multiple myeloma patients who cannot receive a stem cell transplant. ... Read more

January 2, 2019

Triple Combo Therapy May Slow Smoldering Multiple Myeloma Progression into Overt Myeloma, Phase 2 Trial Shows

News

Early treatment with a triple combination therapy containing Empliciti (elotuzumab), Revlimid (lenalidomide), and dexamethasone in patients with smoldering multiple myeloma — a precursor of multiple myeloma — may halt the disease’s ... Read more

December 12, 2018

Phase 2 Myeloma Trial for Investigational CAR T-cell Therapy bb2121 Completes Enrollment

News

An international Phase 2 trial testing the investigational CAR T-cell therapy bb2121 for the treatment of relapsed or refractory multiple myeloma patients has completed patient recruitment, Celgene and bluebird bio announced. The KarMMa ... Read more

November 14, 2018

FDA Clears Way for Trials of FOR46 in Late-stage Multiple Myeloma, Prostate Cancer

News

The U.S. Food and Drug Administration has allowed Fortis Therapeutics’ antibody-drug conjugate FOR46 to begin testing in a Phase 1 clinical trial as a therapy for late-stage multiple myeloma. ... Read more

November 12, 2018

FDA Approves Empliciti Combination for Relapsed or Refractory Multiple Myeloma

News

The U.S. Food and Drug Administration has approved Bristol-Myers Squibb‘s Empliciti (elotuzumab), in combination with Pomalyst (pomalidomide) and low-dose dexamethasone, as a treatment for patients with relapsed or treatment-resistant multiple myeloma. The ... Read more

Pin It on Pinterest